Related Experiment Video
Updated: Jul 8, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Targeted Antiestrogens to Prevent Breast Cancer
1Lynn Sage Breast Cancer Research Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 E. Chicago Avenue, 8258 Olson, Chicago, IL 60611, USA.
Abstract:
Tamoxifen, the first selective estrogen receptor modulator (SERM), has provided invaluable laboratory and clinical evidence that such drugs can reduce the risk of breast cancer and increase bone density. Raloxifene is available for the prevention of osteoporosis, and preliminary studies show a decrease in breast cancer risk. On the basis of current information about the pharmacology of SERMs, a large breast cancer prevention trial called study of tamoxifen and raloxifene (STAR) has started in the USA. Results should be available in the next seven years.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Related Concept Videos
Drugs that Stabilize Microtubules
Mitogens and the Cell Cycle
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists